Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.

TitleDevelopment of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Publication TypeJournal Article
Year of Publication2004
AuthorsAlméras, N, Després, J-P, Villeneuve, J, Demers, M-F, Roy, M-A, Cadrin, C, Mottard, J-P, Bouchard, R-H
JournalJ Clin Psychiatry
Volume65
Issue4
Pagination557-64
Date Published2004 Apr
ISSN0160-6689
KeywordsAdult, Antipsychotic Agents, Benzodiazepines, Biomarkers, Carrier State, Cholesterol, HDL, Coronary Artery Disease, Cross-Sectional Studies, Factor Analysis, Statistical, Fasting, Health Surveys, Humans, Hypertriglyceridemia, Insulin, Male, Metabolic Syndrome, Obesity, Olanzapine, Prevalence, Psychotic Disorders, Risk Factors, Risperidone, Weight Gain
Abstract

BACKGROUND: It is important to assess cardiovascular risk factors to properly verify the potential consequences of atypical antipsychotic-related weight gain. The objective of the present study was to evaluate whether 2 atypical antipsychotics differ regarding their impact on the cardiovascular disease risk profile compared with a reference group.METHOD: We conducted a cross-sectional, multicenter study to assess anthropometric indices of obesity and to obtain a comprehensive fasting metabolic risk profile. Either risperidone or olanzapine had to be prescribed as the first and only antipsychotic for a minimum of 6 months. Patients were compared with a reference group of nondiabetic men. Data were collected from August 1999 to August 2001.RESULTS: Eighty-seven patients treated with olanzapine (N = 42) or risperidone (N = 45) were evaluated. Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2.01 +/-1.05 vs. 1.34 +/-0.65 mmol/L, p < or =.05), lower high-density lipoprotein (HDL)-cholesterol levels (0.92 +/-0.17 vs. 1.04 +/- 0.21 mmol/L, p < or =.05), higher cholesterol/HDL-cholesterol ratios (5.62 +/-1.70 vs. 4.50 +/- 1.44, p < or =.05), higher apolipoprotein B levels (1.07 +/- 0.35 vs. 0.92 +/- 0.27 g/L, p < or =.05), smaller low-density lipoprotein peak particle diameters (252.6 +/-4.1 vs. 255.2 +/-4.3 A, p <.01), and higher fasting insulin concentrations (103.9 +/- 67.6 vs. 87.5 +/- 56.1 pmol/L, p < or =.05) than risperidone-treated patients. Moreover, 33% of olanzapine-treated patients were carriers of 3 atherogenic features of the metabolic syndrome as opposed to a prevalence of only 11% of risperidone-treated patients.CONCLUSION: These results suggest that olanzapine-treated patients are characterized by a more deteriorated metabolic risk factor profile compared with risperidone-treated patients. These observations raise concerns about the potential differential long-term deleterious effects of some antipsychotics, such as olanzapine, on cardiovascular health.

DOI10.4088/jcp.v65n0417
Alternate JournalJ Clin Psychiatry
PubMed ID15119921